Germline CD95 (also known as FAS, APT1 and APO1) gene mutations have been associated with benign lymphoproliferative diseases and autoimmune processes. Somatic mutations have been reported in human tumours, including lymphomas. Since marginal zone B cell lymphomas usually arise in a background of chronic inflammation, often of autoimmune origin, we searched for CD95 gene mutations in an unselected series of marginal zone B cell lymphomas. The CD95/FAS full coding region, comprising exon-intron junctions, was amplified from genomic DNA by polymerase chain reaction (PCR) in 10 separate reactions. PCR products were analysed by single-strand conformation polymorphism (SSCP) and visualised by silver staining. Bands exhibiting an altered electrophoretic mobility were sequenced. Twenty-seven cases of marginal zone B cell lymphomas of whom fresh or frozen tumour material was available (18 extranodal, five splenic and four nodal) were studied. Previously described silent polymorphisms in exons 7 (C836T) and 3 (T416C) were detected in 42% and in 19% of the cases, respectively. One silent T-to-A substitution at bp 431, within exon 3, was found in one case. Our results did not reveal the presence of CD95 somatic mutations in unselected cases of marginal zone B cell lymphomas. On the basis of our data, we cannot rule out that other genes coding for proteins involved in the CD95-induced apoptotic pathway might be altered. However, this pathway does not seem to play an important role in the pathogenesis of these lymphoma subtypes. Leukemia (2000) 14, 446-448.
Introduction
The loss of apoptosis mechanisms has been shown to play a fundamental role in the pathogenesis of human tumours. 1 The CD95 receptor (Fas/Apo-1), which is a member of the nerve growth factor/tumour necrosis factor (NGF/TNF) death receptors superfamily, plays an important role in the exogenously induced apoptosis, in the peripheral deletion of antigenprimed potentially autoreactive T and B cells and of virusinfected and cancer cells. 1, 2 Locus 10q24, where the CD95 gene is mapped, may be deleted in malignant lymphomas, 3 and germline CD95 gene mutations cause benign lymphoproliferative diseases and autoimmune processes. [4] [5] [6] [7] Of interest, marginal zone B cell lymphomas often arise in a context of chronic inflammation, often of autoimmune origin, and are supposed to derive from autoreactive clones. 8, 9 Since somatic CD95 gene mutations have been reported to occur in human tumours, comprising lymphomas, [10] [11] [12] [13] [14] [15] [16] [17] we searched for CD95 gene mutations in a series of marginal zone B cell lymphomas. 
Materials and methods
We studied 27 consecutive cases of marginal zone B cell lymphomas. The histological diagnosis was made according to the Revised European-American Classification of Lymphoid Neoplasms. 18 Genomic DNA was extracted from frozen lymphoma biopsies of extranodal marginal zone B cell lymphomas with the QIAamp Tissue kit following the manufacturer's instructions (Qiagen, Basel, Switzerland), and from matched peripheral blood samples as previously described. 19 The CD95/FAS full coding region, comprising exon-intron junctions, was amplified by polymerase chain reaction (PCR) from genomic DNA using published primers.
12,13 Exons 1-8 were amplified in single PCR reactions, whilst exon 9 was subdivided into two segments. PCR amplification conditions were optimised for each couple of primers. PCR products were analysed by single-strand conformation polymorphism (SSCP) on a 0.75 × MDE gel (FMC, Rockland, ME, USA), run overnight at room temperature and visualised by silver staining. The CEM cell line and a known mutated lymphoma sample were amplified as positive controls for exon 7 and 9.1, respectively. Any cases exhibiting differences in the electrophoresis mobility were sequenced, in both directions, using fluorescent sequencing technology on an ABI 377 sequencer (Perkin-Elmer, Norwalk, CT, USA) from PCR products purified with the QIAquick PCR Purification Kit (Qiagen). DNA sequences were compared with the normal CD95 gene in the GenBank database using the Basic Local Alignment Search Tool (BLAST) software, available at the National Center for Biotechnology Information.
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Results and discussion
Twenty-seven cases of marginal zone B cell lymphomas (18 extranodal, five splenic and four nodal) were studied. The primary extranodal disease site was gastric in 13 cases, cutaneous in three, pulmonary and conjunctival in one case each. DNA derived from two different involved sites was available in three cases.
SSCP analysis of exon 7 PCR products revealed similarly altered bands in 13 out of the 27 cases (42%; 95% CI, 23-63%). DNA extracted both from normal matched peripheral blood, available in five cases, and from different lymphoma samples, also exhibited the same pattern, suggesting the presence of polymorphism rather than somatic mutation. Indeed, DNA sequencing confirmed that all the mutations were due to the known C836T polymorphism. 21 SSCP revealed exon 3 alterations in six cases. Five cases (19%; 95% CI 7-39%) resulted due to the already described T416C polymorphism. 21 One revealed a T-to-A nucleotide change at bp 431. We could not exclude a polymorphism in this case since normal DNA was not available. However, the mutation did not deter-mine any amino acid variation. Somatic mutations within the CD95 gene have been described in bladder cancer, in nonsmall cell lung cancer, in multiple myeloma, and in malignant melanoma, but not in colorectal cancer. [10] [11] [12] 17, 22 Contrary to one previous report of CD95 mutations in 11% of a series of non-Hodgkin's lymphomas, 13 we did not find any mutations in our series of 27 marginal zone B cell lymphomas. By dilution of positive DNA from the CEM cell line, bearing the C836T polymorphism, with normal DNA, we were able to detect abnormal migrating bands in the presence of at least 10-20% of positive genomic DNA, similarly to previous reports: 23 all cases selected for the analysis presented a sufficient pathological infiltrate, as assessed by histologic examination or by cytofluorimetric methods. The vast majority of previously reported lymphoma patients with CD95 gene mutations had overt underlying autoimmune disorders. 13 Our cases were devoid of systemic concomitant autoimmune conditions. In a limited series of patients with lymphoproliferative disorders associated with Sjö gren's syndrome or type II mixed cryoglobulinemia, no CD95 germline mutations were apparently detected, but only four of the nine exons coding for the gene were analysed. 24 Autoimmune disorders with variable patterns of clinical features can be associated with germline CD95 mutations, 25, 26 hence, it might be suggested that lymphomas arising in these patients might be more frequently associated with CD95 mutations. Our results do not confirm the association of CD95 mutations with extranodal lymphomas, and a pathogenic role of CD95 mutations might be limited to the human lymphoproliferative syndrome associated with autoimmune manifestations. [25] [26] [27] In fact, in marginal zone lymphomas, especially in the extranodal MALT type subset, other anti-apoptosis mechanisms seem to be present and are likely to be more relevant, such as the recently reported fusion protein AP12/MLT determined by the recurrent t(11;18)(q21;q21) chromosomal translocation, which can be detected in approximately one third of the cases of extranodal marginal zone lymphoma. 28 Indeed, the rearrangement of the apoptosis inhibitor gene API-2 may result in a survival advantage for the lymphoma B cell clones. Less commonly, MALT B cell lymphomas carry a t(1;14)(p22;q32) that show a recurrent breakpoint upstream of the promoter of a novel gene, BCL10, which contains an amino-terminal caspase recruitment domain (CARD) homologous to that found in several apoptotic molecules. Wild-type BCL10 induces apoptosis, whereas mutant forms have lost this activity, and it has been speculated that inactivating mutations and over-expression of BCL10 might confer to the lymphoma an increased capacity of autonomous growth. 29, 30 Our data do not rule out that other genes coding for proteins involved in the CD95-induced apoptotic pathway might be altered. However, this pathway does not seem to play an important role in the pathogenesis of sporadic, unselected, marginal zone B cell lymphoma cases.
